EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival

Anna Andrzejczak iD, Bartosz Małkiewicz iD, Krzysztof Tupikowski, Kuba Ptaszkowski iD, Tomasz Szydełko, Lidia Karabon iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25136860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Anna Andrzejczak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Genetic and Epigenetic of Human Diseases, Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therap…. Hauptthemen laut MEDLINE: Receptors, Tumor Necrosis Factor, Member 14, Polymorphism, Single Nucleotide, Carcinoma, Renal Cell, Antigens, CD. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation of Count Jakub Potocki (decision 16.12.2019), statutory funds from Hirszfeld Institute of Immunology and Experimental Therapy, research grants from…, Foundation of Count Jakub Potocki (Fundacja im. hr. Jakuba Potockiego), Hirszfeld Institute of Immunology and Experimental Therapy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) accounts for approximately 90–95% of all kidney cancers in adults, with clear cell RCC (ccRCC) being the most frequently identified subtype. RCC is known for its responsiveness to immunotherapy, making it an area of significant research interest. Immune checkpoint (IC) molecules, which regulate immune surveillance, are established therapeutic targets in RCC. The aim of this study was to analyze the influence of HVEM and CD160 gene polymorphisms on ccRCC susceptibility and patient overall survival (OS) over a ten-year period of observation. We genotyped three HVEM single nucleotide polymorphisms (SNPs): rs1886730, rs2234167, and rs8725, as well as two CD160 SNPs: rs744877 and rs2231375, in 238 ccRCC patients and 521 controls. Our findings indicated that heterozygosity within rs2231375 and/or rs2234167 increases ccRCC risk. Furthermore, in women, heterozygosity within HVEM SNPs rs8725 and rs1886730 is also associated with an increased ccRCC risk. The presence of a minor allele for rs1886730, rs2234167, rs8725, and rs2231375 was also correlated with certain clinical features of ccRCC. Moreover, rs1886730 was found to be associated with OS. In conclusion, our study highlights an association between HVEM and CD160 polymorphisms and the risk of developing ccRCC as well as OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Tumor Necrosis Factor, Member 14Polymorphism, Single NucleotideCarcinoma, Renal CellAntigens, CDKidney NeoplasmsGenetic Predisposition to DiseaseGPI-Linked ProteinsHumansFemaleMaleMiddle AgedAgedReceptors, ImmunologicAdultCase-Control StudiesGenotype

Stichwörter der Autor:innen

CD160HVEMclear cell renal cell carcinoma (ccRCC)disease riskimmune checkpointoverall survivalsingle nucleotide gene polymorphism (SNP)

Substanzen

Receptors, Tumor Necrosis Factor, Member 14Antigens, CDCD160 protein, humanTNFRSF14 protein, humanGPI-Linked ProteinsReceptors, Immunologic

Autor:innen und Institutionen

  • Laboratory of Genetic and Epigenetic of Human Diseases, Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
  • Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland.
  • Subdivision of Urology, Lower Silesian Center for Oncology, Pulmonology and Hematology, 53-413 Wroclaw, Poland.
  • Department of Clinical Biomechanics and Physiotherapy in Motor System Disorders, Wroclaw Medical University, 50-368 Wroclaw, Poland.

ORCID-Profile: Anna Andrzejczak, Bartosz Małkiewicz, Kuba Ptaszkowski, Lidia Karabon

Förderung

  • Foundation of Count Jakub Potocki (decision 16.12.2019), statutory funds from Hirszfeld Institute of Immunology and Experimental Therapy, research grants from…
  • Foundation of Count Jakub Potocki (Fundacja im. hr. Jakuba Potockiego)
  • Hirszfeld Institute of Immunology and Experimental Therapy
  • Wroclaw Medical University

Zitieren

APA

Andrzejczak, A., Małkiewicz, B., Tupikowski, K., Ptaszkowski, K., Szydełko, T., & Karabon, L. (2024). Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25136860

Vancouver

Andrzejczak A, Małkiewicz B, Tupikowski K, Ptaszkowski K, Szydełko T, Karabon L. Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25136860

BibTeX
@article{Andrzejczak2024,
  author = {Andrzejczak, Anna and Małkiewicz, Bartosz and Tupikowski, Krzysztof and Ptaszkowski, Kuba and Szydełko, Tomasz and Karabon, Lidia},
  title = {Effect of HVEM/CD160 Variations on the Clear Cell Renal Carcinoma Risk and Overall Survival},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25136860}
}
Kostenlos starten →